Literature DB >> 15115639

Recent advances in clinical use of opioids.

Eric Chevlen1.   

Abstract

Opioid therapy for pain is the subject of numerous randomized clinical trials. Opioids are being developed for delivery by a wide variety of mechanisms. New opioids are becoming available for clinical use. This review surveys recent developments in these clinical trials and provides an overview of what may be expected in the near future for opioid management of pain.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15115639     DOI： 10.1007/s11916-004-0053-5

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN： 1534-3081


  38 in total

1.  Effectiveness of Stadol NS (butorphanol tartrate) with ibuprofen in the treatment of pain after laser-assisted uvulopalatopharyngoplasty.

Authors:  M Madani
Journal:  J Oral Maxillofac Surg       Date:  2000-10       Impact factor: 1.895

2.  Use of TTS fentanyl as a single opioid for cancer pain relief: a safety and efficacy clinical trial in patients naive to mild or strong opioids.

Authors:  Kyriaki Mystakidou; Sofia Befon; Eleni Tsilika; Kostas Dardoufas; Stavroula Georgaki; Lambros Vlahos
Journal:  Oncology       Date:  2002       Impact factor: 2.935

3.  Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).

Authors:  P H Coluzzi; L Schwartzberg; J D Conroy; S Charapata; M Gay; M A Busch; J Chavez; J Ashley; D Lebo; M McCracken; R K Portenoy
Journal:  Pain       Date:  2001-03       Impact factor: 6.961

4.  Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.

Authors:  Mark Palangio; Donald W Northfelt; Russell K Portenoy; Daniel Brookoff; Ralph T Doyle; Bruce E Dornseif; Michael C Damask
Journal:  J Pain Symptom Manage       Date:  2002-05       Impact factor: 3.612

5.  Novel receptor mechanisms for heroin and morphine-6 beta-glucuronide analgesia.

Authors:  G C Rossi; G P Brown; L Leventhal; K Yang; G W Pasternak
Journal:  Neurosci Lett       Date:  1996-09-20       Impact factor: 3.046

6.  Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial.

Authors:  Jacques R Caldwell; Ronald J Rapoport; Jeffrey C Davis; Howard L Offenberg; Howard W Marker; Sanford H Roth; William Yuan; Lise Eliot; Najib Babul; Pia Mikkelsen Lynch
Journal:  J Pain Symptom Manage       Date:  2002-04       Impact factor: 3.612

7.  Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain.

Authors:  Russell K Portenoy; Andréa Sciberras; Lise Eliot; Gordon Loewen; Jackie Butler; John Devane
Journal:  J Pain Symptom Manage       Date:  2002-04       Impact factor: 3.612

8.  Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine.

Authors:  A P Vielvoye-Kerkmeer; C Mattern; M P Uitendaal
Journal:  J Pain Symptom Manage       Date:  2000-03       Impact factor: 3.612

9.  A double-blind, single-dose comparison of the analgesic efficacy of tramadol/acetaminophen combination tablets, hydrocodone/acetaminophen combination tablets, and placebo after oral surgery.

Authors:  James R Fricke; Rezaul Karim; Donna Jordan; Norman Rosenthal
Journal:  Clin Ther       Date:  2002-06       Impact factor: 3.393

10.  Randomized, double-blind, placebo-controlled comparison of the analgesic efficacy of oxycodone 10 mg/acetaminophen 325 mg versus controlled-release oxycodone 20 mg in postsurgical pain.

Authors:  Arnold R Gammaitoni; Bradley S Galer; Scott Bulloch; Peter Lacouture; Frank Caruso; Tina Ma; Thomas Schlagheck
Journal:  J Clin Pharmacol       Date:  2003-03       Impact factor: 3.126
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.